Greetings,
Every Monday afternoon, we send out a stock trade idea to some of MarketBeat's best and most valued subscribers.
We think you are one of those people...but you are not on our alert distribution list yet.
This once a week alert is sent out via SMS so that you can see it right away.
Last week's alert was very popular with our subscribers, you won't want to miss out on the next alert -- and it doesn't cost you a thing.
We're going to send out another trade idea on Monday around noon, and I want to make sure that you're able to see it.
Add your name to the distribution list here.
You'll thank me on Tuesday morning.
Matthew Paulson
MarketBeat
3 Stocks You'll Wish You Bought Before 2026
Written by Chris Markoch. Posted: 12/3/2025.
Key Takeaways
- These three up-and-coming stocks have delivered triple-digit gains in 2025 and continue to show strong momentum.
- Key catalysts—including clinical milestones, revenue acceleration, and consumer demand—suggest more upside ahead.
- Analysts stay optimistic, with price targets suggesting possible double- or triple-digit gains from current levels.
Many investors profited from the artificial intelligence (AI) trade in 2025, but several up-and-coming stocks in other sectors also posted impressive gains this year.
These three names remain small-cap — the largest has a market cap just above $4 billion — yet they've made strong moves, underscoring that time in the market often beats trying to time it.
Executive Order 14330: Trump's Biggest Yet (Ad)
While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies...
Discover how to invest in the fund Trump uses to collect this income >>If investors could see the future with absolute clarity, investing would be easy. The future is rarely clear, and a bullish outcome is not guaranteed. Still, the charts speak for themselves: investors who bought these stocks and held through rough stretches are reaping the rewards today, and the rallies may have room to continue.
Biotech Breakthrough: A Small Cap With a Big 2026 FDA Catalyst
Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company that recently reported positive clinical data for its first-in-class PI3K/mTOR inhibitor targeting HR+/HER2- metastatic breast cancer. Its pivotal Phase 3 VIKTORIA trial is underway, and some investors believe the company could receive U.S. Food & Drug Administration (FDA) approval in 2026.
Investors have been front-running those expectations, pushing CELC stock up more than 660%, with nearly all of those gains occurring since the end of July. At $99.30 as of this writing, the stock sits within about 3% of its consensus price target. Meanwhile, Jefferies raised its price target on the stock to $134 from $108 on Dec. 2.
The biggest risk is funding the commercialization phase. In its most recent earnings report, Celcuity showed a strengthened balance sheet with $455 million in cash, cash equivalents, and short-term investments, up about 72% year-over-year (YOY). Management believes those resources will be sufficient until commercialization begins.
Fintech Disruptor Turning Revenue Growth Into Real Momentum
At a time when traditional banks offer fewer affordable options, Dave Inc. (NASDAQ: DAVE) stands out. The Los Angeles-based fintech is best known for its Dave app.
The app delivers affordable, transparent financial tools that help users — many living paycheck to paycheck — avoid overdraft fees, budget more effectively, and access short-term cash when needed. The company recently reported a 64% YOY increase in revenue and an 85% beat in adjusted earnings per share (EPS).
DAVE stock is up roughly 120% in 2025, and analysts see further upside. As of this writing the stock trades at $208.24, and the consensus price target is $304.25 — more than 46% higher.
Some investors may be wary of a forward price-to-earnings (P/E) ratio near 119. But analysts forecast earnings growth of roughly 117% over the next 12 months — growth that could justify a higher multiple as the company scales.
Resale Retail Winner Riding a Massive Consumer Shift
It's been another challenging year for consumer staples stocks, but ThredUp Inc. (NASDAQ: TDUP) has been a notable exception. TDUP is up more than 430% in 2025 despite a roughly 29% pullback during the three months ending Dec. 1.
The company operates an online consignment marketplace — a model that resonates as many consumers tighten their budgets. The thrift and resale market was a $49 billion industry in 2024 and is projected to grow to $74 billion by 2029.
TDUP is the smallest of the three names, and short interest above 17% indicates active trading. Still, the company's Q3 earnings showed strong year-over-year (YOY) revenue growth, record new-buyer acquisition, and a 37% YOY increase in orders.
This could be a shorter-term, volatile trade. However, younger consumers — who form ThredUp's core market — are likely to remain budget-conscious for some time, which helps explain why analysts put TDUP's consensus price target at $12.50, roughly a 68% upside from its closing price on Dec. 1.
We empower investors to make better investment decisions by delivering real-time financial information and unbiased investment analysis.
This email message is a paid sponsorship provided by MarketBeat Alerts, a third-party advertiser of MarketBeat. Why did I get this message?.
If you need help with your account, feel free to contact our U.S. based support team at contact@marketbeat.com.
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
Copyright 2006-2025 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, S.D. 57103. USA..